Expanding Medicare’s price controls into the private market would make the business of drug discovery all but impossible in the United States — and mark the end of America’s reign as the world’s leading source of life-saving medicines.
In November, a group of Democrats in the U.S. House made clear that they’ll sacrifice medical innovation for lower drug prices if they ever reclaim Congress.
Patients today and tomorrow will be the losers in that trade.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Democrats Can’t End Private-Sector Drug Innovation Fast Enough
Sally C. Pipes
Expanding Medicare’s price controls into the private market would make the business of drug discovery all but impossible in the United States — and mark the end of America’s reign as the world’s leading source of life-saving medicines.
In November, a group of Democrats in the U.S. House made clear that they’ll sacrifice medical innovation for lower drug prices if they ever reclaim Congress.
Patients today and tomorrow will be the losers in that trade.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.